256 Newsroom — Uganda's Digital News Infrastructure
Business

GSK plans phase 3 after mRNA flu vaccine beats standard shots - Fierce Biotech

Published by FierceBiotech By Nick Paul Taylor · 1 September 2026 at 12:43
Share
GSK plans phase 3 after mRNA flu vaccine beats standard shots - Fierce Biotech
Image · FierceBiotech

What the report says

GSK has linked its mRNA | GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, emboldening the company to start a pivotal study this month.

Read the full report at FierceBiotech →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Fresh Dispute Erupts Over Wakiso Market Stall AllocationNile Post Eight Arrested Over Alleged Destruction of Coffee, Cocoa, Banana Plants in LuweeroNile Post 256 Newsroom What Tooro story tells us about trust in news - Daily MonitorDaily Monitor 256 Newsroom Why World Vision is exiting Rakai’s Kyarurangira after 20 years - Daily MonitorDaily Monitor Uganda’s informal economy seeks strength in numbersThe Observer 256 Newsroom Gen Saleh Calls for Review of Caged-Fishing and Coffee-Farming Projects - ChimpReportsChimpReports